EP1437352A4 — BENZYMIDAZOLE COMPOUND, PROCESS FOR PRODUCING AND USING THE SAME
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2004-12-08 · 21y expired
What this patent protects
A compound represented by the formula (I) (wherein the symbols have the same meanings as in the description) or a salt thereof, which is a prodrug of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole and has excellent stability to acids. The comp…
USPTO Abstract
A compound represented by the formula (I) (wherein the symbols have the same meanings as in the description) or a salt thereof, which is a prodrug of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole and has excellent stability to acids. The compound has the following effects. (1) It has excellent in vivo activities such as antiulcerous activity, gastric hydrochloric acid secretion inhibitory activity, mucosal protective activity, and antihelicobacter pylori activity. (2) It is lowly toxic. (3) It is highly stable to acids (it eliminates the necessity of enteric formulation to attain cost reduction and is easy to take because of a decrease in preparation size). (4) It is absorbed more rapidly than enteric drugs (the gastric hydrochloric acid secretion inhibitory activity is exhibited earlier). (5) It is effective for long.
Drugs covered by this patent
- Dexilant (DEXLANSOPRAZOLE) · Takeda
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.